Dewitte, Heleen

The dawn of mRNA vaccines: the COVID-19 case

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release

SARS-CoV-2 and COVID-19 ResearchRNA Interference and Gene Delivery

Cited by 504

Three decades of messenger RNA vaccine development

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 342

Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA

Verbeke, R., Lentacker, I., Wayteck, L., Breckpot, K., Van Bockstal, M., Descamps, B., Vanhove, C., De Smedt, S. C., & Dewitte, H. (2017) · Journal of Controlled Release

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 132

Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon

Broos, K., Van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C., Dewitte, H., Verbeke, R., Lentacker, I., Thielemans, K., & Breckpot, K. (2016) · Molecular Therapy — Nucleic Acids

RNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Cited by 121

Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger.

Devoldere, J., Dewitte, H., De Smedt, S. C., & Remaut, K. (2016) · Drug Discovery Today

RNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Cited by 112

The ReNAissanCe of mRNA-based cancer therapy

Van Lint, S., Renmans, D., Broos, K., Dewitte, H., Lentacker, I., Heirman, C., Breckpot, K., & Thielemans, K. (2015) · Expert Review of Vaccines

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 95